S 1052
115th Congress
Senate
Health
Drug safety, medical device, and laboratory regulation
Health information and medical records
Product development and innovation
BENEFIT Act of 2017
Introduced: May 4, 2017
Introduced by:
Wicker, Roger F.
Republican
· Mississippi
See on congress.gov
Everywhere this bill has been
10 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 11, 2017
Referred to the Subcommittee on Health.
Aug 4, 2017
Referred to the House Committee on Energy and Commerce.
Aug 4, 2017
Received in the House.
Aug 3, 2017
Message on Senate action sent to the House.
Aug 3, 2017
Passed Senate without amendment by Unanimous Consent. (text: CR S4788)
Aug 3, 2017
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S4788)
Aug 3, 2017
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S4787-4788)
Aug 3, 2017
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S4787-4788)
May 4, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 4, 2017
Introduced in Senate
Plain-English summary
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3
Cosponsors
1